Literature DB >> 23455764

MRI for response assessment in metastatic bone disease.

F E Lecouvet1, A Larbi, V Pasoglou, P Omoumi, B Tombal, N Michoux, J Malghem, R Lhommel, B C Vande Berg.   

Abstract

BACKGROUND: Beyond lesion detection and characterisation, and disease staging, the quantification of the tumour load and assessment of response to treatment are daily expectations in oncology.
METHODS: Bone lesions have been considered "non-measurable" for years as opposed to lesions involving soft tissues and "solid" organs like the lungs or liver, for which response evaluation criteria are used in every day practice. This is due to the lack of sensitivity, specificity and measurement capabilities of imaging techniques available for bone assessment, i.e. skeletal scintigraphy (SS), radiographs and computed tomography (CT).
RESULTS: This paper reviews the possibilities and limitations of these techniques and highlights the possibilities of positron emission tomography (PET), but mainly concentrates on magnetic resonance imaging (MRI).
CONCLUSION: Practical morphological and quantitative approaches are proposed to evaluate the treatment response of bone marrow lesions using "anatomical" MRI. Recent developments of MRI, i.e. dynamic contrast-enhanced (DCE) imaging and diffusion-weighted imaging (DWI), are also covered. KEY POINTS: • MRI offers improved evaluation of skeletal metastases and their response to treatment. • This new indication for MRI has wide potential impact on radiological practice. • MRI helps meet the expectations of the oncological community. • We emphasise the practical aspects, with didactic cases and illustrations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23455764     DOI: 10.1007/s00330-013-2792-3

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  47 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Response evaluation of bone metastases in breast cancer: value of magnetic resonance imaging.

Authors:  P Saip; N Tenekeci; A Aydiner; M Dinçer; S Inanç; C Demir; E N Oral; E Topuz
Journal:  Cancer Invest       Date:  1999       Impact factor: 2.176

Review 3.  Diffusion-weighted magnetic resonance imaging and its application to cancer.

Authors:  Elizabeth M Charles-Edwards; Nandita M deSouza
Journal:  Cancer Imaging       Date:  2006-09-13       Impact factor: 3.909

4.  Measurement of perfusion and permeability from dynamic contrast-enhanced MRI in normal and pathological vertebral bone marrow.

Authors:  Andreas Biffar; Steven Sourbron; Gerwin Schmidt; Michael Ingrisch; Olaf Dietrich; Maximilian F Reiser; Andrea Baur-Melnyk
Journal:  Magn Reson Med       Date:  2010-07       Impact factor: 4.668

Review 5.  Bone metastases: assessment of therapeutic response through radiological and nuclear medicine imaging modalities.

Authors:  V Vassiliou; D Andreopoulos; S Frangos; N Tselis; E Giannopoulou; S Lutz
Journal:  Clin Oncol (R Coll Radiol)       Date:  2011-04-29       Impact factor: 4.126

6.  MR imaging of bone marrow in children with osteosarcoma: effect of granulocyte colony-stimulating factor.

Authors:  S P Ryan; E Weinberger; K S White; D W Shaw; K Patterson; V Nazar-Stewart; J Miser
Journal:  AJR Am J Roentgenol       Date:  1995-10       Impact factor: 3.959

7.  Whole-body MRI versus whole-body MDCT for staging of multiple myeloma.

Authors:  Andrea Baur-Melnyk; Sonja Buhmann; Christoph Becker; Stefan Oswald Schoenberg; Nicola Lang; Reiner Bartl; Maximilian Ferdinand Reiser
Journal:  AJR Am J Roentgenol       Date:  2008-04       Impact factor: 3.959

Review 8.  Imaging response to systemic therapy for bone metastases.

Authors:  Tobias Bäuerle; Wolfhard Semmler
Journal:  Eur Radiol       Date:  2009-05-26       Impact factor: 5.315

9.  Evaluation of new sclerotic bone metastases in breast cancer patients during treatment.

Authors:  I Ciray; G Aström; I Andréasson; T Edekling; J Hansen; J Bergh; H Ahlström
Journal:  Acta Radiol       Date:  2000-03       Impact factor: 1.701

Review 10.  Imaging metastatic bone disease from carcinoma of the prostate.

Authors:  C Messiou; G Cook; N M deSouza
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

View more
  24 in total

1.  Vertebral sarcoidosis: long-term follow-up with MRI.

Authors:  M Lefere; A Larbi; J Malghem; B Vande Berg; B Dallaudière
Journal:  Skeletal Radiol       Date:  2014-03-29       Impact factor: 2.199

Review 2.  Calcaneal cysts and lipomas: a common pathogenesis?

Authors:  Jacques Malghem; Frédéric Lecouvet; Bruno Vande Berg
Journal:  Skeletal Radiol       Date:  2017-06-14       Impact factor: 2.199

3.  Study of proximal femoral bone perfusion with 3D T1 dynamic contrast-enhanced MRI: a feasibility study.

Authors:  Jean-François Budzik; Guillaume Lefebvre; Gerard Forzy; Mazen El Rafei; David Chechin; Anne Cotten
Journal:  Eur Radiol       Date:  2014-08-14       Impact factor: 5.315

4.  Added Value of Contrast Medium in Whole-Body Hybrid Positron Emission Tomography/Magnetic Resonance Imaging: Comparison between Contrast-Enhanced and Non-Contrast-Enhanced Protocols.

Authors:  Filiz Celebi; Emetullah Cindil; Dauren Sarsenov; Bulent Unalan; Cem Balcı
Journal:  Med Princ Pract       Date:  2019-06-17       Impact factor: 1.927

5.  Synthetic MRI of the knee: new perspectives in musculoskeletal imaging and possible applications for the assessment of bone marrow disorders.

Authors:  Lydia Chougar; Akifumi Hagiwara; Christina Andica; Masaaki Hori; Shigeki Aoki
Journal:  Br J Radiol       Date:  2018-01-15       Impact factor: 3.039

Review 6.  Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma.

Authors:  Julie C Dutoit; Koenraad L Verstraete
Journal:  Skeletal Radiol       Date:  2017-03-13       Impact factor: 2.199

7.  Early detection with MRI of incomplete treatment of spine metastases after percutaneous cryoablation.

Authors:  Guillaume Gravel; Lambros Tselikas; Benjamin Moulin; Steven Yevich; Eric Baudin; Antoine Hakime; Salma Moalla; Fadila Mihoubi; Corinne Balleyguier; Thierry de Baere; Frederic Deschamps
Journal:  Eur Radiol       Date:  2019-03-15       Impact factor: 5.315

8.  Magnetic resonance-guided focused ultrasound for the treatment of painful bone metastases: role of apparent diffusion coefficient (ADC) and dynamic contrast enhanced (DCE) MRI in the assessment of clinical outcome.

Authors:  Michele Anzidei; Alessandro Napoli; Beatrice Sacconi; Fabrizio Boni; Vincenzo Noce; Michele Di Martino; Luca Saba; Carlo Catalano
Journal:  Radiol Med       Date:  2016-08-27       Impact factor: 3.469

9.  The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma.

Authors:  Julie C Dutoit; Matthias A Vanderkerken; Joris Anthonissen; Frederick Dochy; Koenraad L Verstraete
Journal:  Eur Radiol       Date:  2014-08-09       Impact factor: 5.315

10.  Use of apparent diffusion coefficient as a response biomarker in bone: effect of developing sclerosis on quantified values.

Authors:  C Messiou; D J Collins; V A Morgan; D Bianchini; J S de Bono; N M de Souza
Journal:  Skeletal Radiol       Date:  2013-11-24       Impact factor: 2.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.